The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses

British Journal of Clinical Pharmacology

Volumn 72, Issue 1, 2011, Pages 39-50

  Ring, Arne ^a,b   Port, Andreas ^a   Graefe Mody, E Ulrike ^a   Revollo, Ivette ^a   Iovino, Mario ^a   Dugi, Klaus A ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

BI 1356; ECG; Linagliptin; Thorough QT study

Indexed keywords

DRUG METABOLITE; LINAGLIPTIN; MOXIFLOXACIN; PLACEBO;

ADULT; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CAUCASIAN; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DETERMINATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; EPISTAXIS; FATIGUE; FEMALE; HEADACHE; HEART RATE; HEMATOMA; HUMAN; ISCHIALGIA; MALE; NORMAL HUMAN; OPEN STUDY; PHARMACODYNAMICS; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; CROSS-OVER STUDIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; PURINES; QUINAZOLINES; YOUNG ADULT;

EID: 79953217579     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.03931.x     Document Type: Article

References (37)

1. Hüttner S, Graefe-Mody EU, Withopf B, Ring A, Dugi KA. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase-4, in healthy male volunteers. J Clin Pharmacol 2008; 48: 1171-8.
2. Eckhardt M, Langkopf E, Mark M, Tadyyon M, Thomas L, Nar H, Pfrengle W, Guth B, Lotz R, Sieger P, Fuchs H, Himmelsbach F. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3, 7-dihydropurine-2, 6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem 2007; 50: 6450-3.
3. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3, 7-dihydro-purine-2, 6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 2008; 325: 175-82.
4. Campbell RK. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus. Ann Pharmacother 2007; 41: 51-60.
5. Deacon CF, Ahrén B, Holst JJ. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of type 2 diabetes? Expert Opin Investig Drugs 2004; 13: 1091-102.
6. Langley AK, Suffoletta TJ, Jennings HR. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. Pharmacotherapy 2007; 27: 1163-80.
7. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and non-diabetic humans. Am J Physiol Endocrinol Metab 2004; 287: E119-206.
8. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26: 2929-40.
9. Food and Drug Administration, HHS. International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Fed Regist 2005; 70: 61134-5.
10. Cubeddu LX. QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. Am J Ther 2003; 10: 452-7.
11. Heise T, Graefe-Mody EU, Hüttner S, Ring A, Trommeshauser D, Dugi KA. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab 2009; 11: 786-94.
12. Deacon CF, Holst JJ. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2010; 19: 133-40.
13. Forst T, Uhlig-Laske B, Ring A, Graefe-Mody U, Friedrich C, Herbach K, Woerle H-J, Dugi KA. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes. Diabet Med 2010; 27: 1409-19. DOI: 10.1111/j.1464-5491.2010.03131.x.
14. Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle H-J, Dugi KA. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomised controlled trial. Diabetes Obes Metab 2011; 13: 258-67. DOI: 10.1111/j.1463-1326.2010.01350.x.
15. Taskinen M-R, Rosenstock J, Tamminen I, Kubiak R, Patel S, Dugi KA, Woerle H-J. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011; 13: 65-74. DOI: 10.1111/j.1463-1326.2010.01326.x.
16. Gomis R, Espadero R-M, Jones R, Woerle H-J, Dugi KA. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes. Poster 551-P presented at the 70th Scientific Sessions of the American Diabetes Association, Orlando, Florida, 25-29 June 2010, abstract available online. Available at (last accessed 4 November 2010).
17. Owens DR, Swallow R, Jones P, Dugi KA, Woerle H-J. Linagliptin improves glycemic control in type 2 diabetes patients inadequately controlled by metformin and sulfonylurea without weight gain or hypoglycemia. Poster 548-P presented at the 70th Scientific Sessions of the American Diabetes Association, Orlando, Florida, 25-29 June 2010, abstract available online. Available at (last accessed 4 November 2010).
18. Morganroth J. A definitive or thorough phase 1 QT ECG trial as a requirement for drug safety assessment. J Electrocardiol 2004; 37: 25-9.
19. Bloomfield DM, Krishna R, Hreniuk D, Hickey L, Ghosh K, Bergman AJ, Miller J, Gutierrez MJ, Stoltz R, Gottesdiener KM, Herman GA, Wagner JA. A Thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects. J Clin Pharmacol 2009; 49: 937-46.
20. Moss AJ, Morganroth J. Cardiac effects of ebastine and other antihistamines in humans. Drug Saf 1999; 21: (Suppl. 1): 69-80.
21. Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther 2003; 73: 292-303.
22. Jones B, Kenward MG. Design and Analysis of Cross-Over Trials, 2nd edn. Boca Raton, FL: CRC Press/Taylor and Francis Group, 2003; ISBN 0-412-60640-2.
23. Zhang J, Machado SG. Statistical issues including design and sample size calculation in thorough QT/QTc studies. J Biopharm Stat 2008; 18: 451-67.
24. Zhang X, Silkey M, Schumacher M, Wang L, Raval H, Caulfield JP. Period correction of the QTc of moxifloxacin with multiple predose baseline ECGs is the least variable of 4 methods tested. J Clin Pharmacol 2009; 49: 534-9.
25. Glomb P, Ring A. Use of baseline ECGs in the evaluation of thorough-QT studies with crossover design. 54th Biometric Colloquium, Munich, 2008. Available at, page 233;
26. Ring A. Statistical models for heart rate correction of the QT interval. Stat Med 2010; 29: 786-96.
27. Shah A, Hajain GA. Maximum likelihood approach for estimating the QT correction factor using mixed effects model. Stat Med 2003; 22: 1901-9.
28. Wang Y, Pan G, Balch A. Bias and variance evaluation of QT interval correction methods. J Biopharm Stat 2008; 18: 427-50.
29. th Scientific Sessions of the American Diabetes Association, New Orleans, Louisiana, 05-09 June 2009. Abstract available online at (last accessed 4 November 2010).
30. European Medicines Agency (EMEA). Galvus (vildagliptin) - European Public Assessment Report (EPAR) - Scientific Discussion (2007). Available at (last accessed 04 November 2010).
31. Malik M. Facts, fancies and follies of drug-induced QT/QTc interval shortening. Br J Pharmacol 2009; 159: 70-6.
32. Malik M, Hnatkova K, Batchvarov V. Differences between study-specific and subject-specific heart rate corrections of the QT interval in investigations of drug induced QTc prolongation. Pacing Clin Electrophysiol 2004; 27: 791-800.
33. Schall R, Ring A. Statistical characterisation of QT prolongation. J Biopharm Stat 2010; 20: 543-62.
34. Schall R, Ring A. Mixed models for data from thorough QT studies. Part 1. Assessment of marginal QT prolongation. Pharm Stat 2011; DOI: 10.1002/pst.463.
35. Zhang L, Smith B. Sex differences in QT interval variability and implication on sample size of thorough QT study. Drug Inf J 2007; 41: 619-27.
36. Beasley CM, Dmitrienko A, Mitchell MI. Design and analysis considerations for thorough QT studies employing conventional (10s, 12-lead) ECG recordings. Exp Review Clin Pharmacol 2008; 1: 815-39.
37. Démolis JL, Kubitza D, Tennezé L, Funck-Brentano C. Effect of a single oral dose of moxifloxacin (400mg and 800mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther 2000; 68: 658-66.